“Sustained On- and Off-Treatment Disease Control in Patients With Moderate-to-Severe Atopic Dermatitis Following 12-Week, Open-Label, Once-Daily Abrocitinib 200 Mg: A Post Hoc Analysis of the Phase 3 JADE REGIMEN Study”. SKIN The Journal of Cutaneous Medicine 10, no. 2 (March 10, 2026): s732. Accessed April 27, 2026. https://skin.dermsquared.com/skin/article/view/4025.